MT1013
Phase 3Small molecule
MT1013 is one of 10 small molecule programs targeting Secondary Hyperparathyroidism. It is currently in Phase 3.
1
Indications
4
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Secondary Hyperparathyroidism
#DrugCompanyPhaseTrials
1Zemplar
AbbVieApproved
Sensipar
AmgenApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Rayaldee
OOrganon and Co
Approved
Parsabiv
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
MT1013
SShaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 3
Renvela
SanofiPreclinical
Glucophage
EMD SeronoPreclinical
Forteo
AAlmaject
Preclinical
One-Alpha
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Secondary Hyperparathyroidism2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MT1013. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details